Group One Trading
ZNTL icon

Group One Trading’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Group One Trading’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14,900
Closed -$22.5K – 9326
2025
Q3 		$22.5K Sell
14,900
-10,700
-42% -$16K ﹤0.01% 6608
2025
Q2 		$29.7K Sell
25,600
-44,400
-63% -$58.6K ﹤0.01% 5992
2025
Q1 		$111K Buy
70,000
+20,000
+40% +$43.1K ﹤0.01% 4509
2024
Q4 		$152K Buy
50,000
+44,800
+862% +$147K ﹤0.01% 4158
2024
Q3 		$19.1K Buy
5,200
+200
+4% +$727 ﹤0.01% 5255
2024
Q2 		$20.4K Buy
+5,000
New +$55.8K ﹤0.01% 5209
2023
Q4 		– Sell
-100
Closed -$2.01K – 8314
2023
Q3 		$2.01K Hold
100
– – ﹤0.01% 7043
2023
Q2 		$2.82K Buy
+100
New +$2.4K ﹤0.01% 6964
2021
Q4 		– Sell
-200
Closed -$13K – 8945
2021
Q3 		$13K Hold
200
– – ﹤0.01% 7398
2021
Q2 		$11K Buy
+200
New +$10.7K ﹤0.01% 7488

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Group One Trading's ZNTL Position: Q1 2026 in Review

Group One Trading opened a new position in Zentalis Pharmaceuticals (ZNTL) in Q1 2026: 1,460 shares worth $3.42K. The stake represents ﹤0.01% of the portfolio and ranks #6869 among its holdings. This is a return to the name: Group One Trading previously reported a position in ZNTL as recently as Q2 2025.

Group One Trading first reported a position in ZNTL in Q2 2022 and has held it in 7 quarters since. The position peaked at $433K in Q4 2023. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Group One Trading held 1,460 shares of Zentalis Pharmaceuticals worth $3.42K as of Q1 2026.
  • Zentalis Pharmaceuticals was a new Group One Trading position in Q1 2026.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #6869 holding.
  • Group One Trading first reported a position in Zentalis Pharmaceuticals in Q2 2022 and has held it in 7 quarters since.
  • Group One Trading's Zentalis Pharmaceuticals position peaked at $433K in Q4 2023.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.